Printer Friendly

ROBERT J. TERNANSKY, Ph.D., JOINS LA JOLLA PHARMACEUTICAL TO HEAD INFLAMMATION PROGRAM

 SAN DIEGO, June 10 /PRNewswire/ -- La Jolla Pharmaceutical Co. announced today that Robert J. Ternansky, Ph.D., has joined the company as associate director of Inflammation Research. Ternansky comes to La Jolla Pharmaceutical Co. from Eli Lilly & Co. where he spent nine years in medicinal chemistry in the discovery and development of new compounds to treat infectious diseases. Prior to Lilly, he was a post-doctoral fellow at Stanford University. Ternansky received his Ph.D. in organic chemistry from Ohio State University in 1982 based on the successful total synthesis of dodecahedrane. This work is considered a fundamental milestone in synthetic organic chemistry. Ternansky has published numerous scientific papers and is an inventor on 10 issued U.S. patents.
 La Jolla Pharmaceutical has launched a program to develop inhibitors of the enzyme phospholipase A2 (PLA2) as potential treatments for inflammation and inflammatory diseases based on proprietary technology which the company licensed from the University of California. Diseases caused by inflammation include rheumatoid arthritis, osteoarthritis, asthma and inflammatory bowel disease. There are very strong synergies between the company's new inflammation program and its basic work to develop drugs to treat antibody-mediated diseases such as lupus based on its "Tolerance Technology(TM)."
 "We are extremely pleased to have someone of Dr. Ternansky's stature join the company to lead our Inflammation Research Program," said Joseph Stemler, president and chief executive officer. "This has the potential to be a second technology platform for the company with a number of target diseases in very significant markets." La Jolla Pharmaceutical Co. was founded in 1989 to develop products based on its proprietary "Tolerance Technology(TM)" to treat antibody-mediated diseases. The company is privately held and is headquartered in San Diego.
 -0- 6/10/93
 /CONTACT: Andrew Wiseman, Ph.D., of La Jolla Pharmaceutical, 619-452-6600/


CO: La Jolla Pharmaceutical Co. ST: California IN: MTC SU: PER

MF-JL -- SD003 -- 0394 06/10/93 06:00 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 10, 1993
Words:317
Previous Article:SAGASCO'S EXTENDS TENDER OFFER FOR MAGELLAN PETROLEUM
Next Article:SOFTWARE TOOLWORKS REPORTS NET INCOME FOR FISCAL YEAR ENDED MARCH 31, 1993, VERSUS NET LOSS FOR PRIOR YEAR; BOB LLOYD APPOINTED CEO
Topics:


Related Articles
LA JOLLA PHARMACEUTICAL NAMES HEAD OF CHEMICAL OPERATIONS
KENNETH WOOLCOTT PROMOTED TO GENERAL COUNSEL AT IDEC PHARMACEUTICALS
DR. THOMAS H. ADAMS ELECTED TO LA JOLLA PHARMACEUTICAL BOARD
HECTOR J. GOMEZ, M.D., PH.D., JOINS VERTEX AS VP MEDICAL AFFAIRS
HANS A. de HAAN JOINS LA JOLLA PHARMACEUTICAL AS VICE PRESIDENT, CLINICAL AFFAIRS
T CELL SCIENCES NAMES NEW SCIENTIFIC ADVISORY BOARD MEMBERS
LIDAK PHARMACEUTICALS COMPLETES STAFFING OF ITS CLINICAL DEVELOPMENT ADVISORY PANEL WITH ADDITION OF GALLO
LA JOLLA PHARMACEUTICAL PROMOTES STEVE ENGLE TO CEO
LIDAK PHARMACEUTICALS APPOINTS GERALD J. YAKATAN AS VICE PRESIDENT, DRUG DEVELOPMENT
LA JOLLA PHARMACEUTICAL APPOINTS SENIOR VICE PRESIDENT OF CORPORATE DEVELOPMENT & MARKETING

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters